RECORD // Company

Heron Therapeutics, Inc. /De/

Formerly: AP PHARMA INC /DE/; ADVANCED POLYMER SYSTEMS INC /DE/

Built 2026-11-22T01:01:00Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)

3 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-09 · accession 0001193125-26-452759

ItemValuePeriodFormFiledAccessionReport
Revenue$35,250,0003 months ended 2026-09-3010-Q2026-11-090001193125-26-4527592026-11-22 01:01 UTCReport an error
Net income (loss)$-5,006,0003 months ended 2026-09-3010-Q2026-11-090001193125-26-4527592026-11-22 01:01 UTCReport an error
Cash and cash equivalents$11,595,000at 2026-09-3010-Q2026-11-090001193125-26-4527592026-11-22 01:01 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0000818033
Ticker
HRTX
EIN
942875566
CUSIP
427746102
Record ID
sx:sec:0000818033

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

38 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-16SEC EDGAR company profile2026-11-22 01:01 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-16SEC EDGAR company profile2026-11-22 01:01 UTCReport an error
State of incorporationDE2026-11-16SEC EDGAR company profile2026-11-22 01:01 UTCReport an error
Fiscal year end (MMDD)12312026-11-16SEC EDGAR company profile2026-11-22 01:01 UTCReport an error
Business address4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA, 921212026-11-16SEC EDGAR company profile2026-11-22 01:01 UTCReport an error
ExchangesNasdaq2026-11-16SEC EDGAR company profile2026-11-22 01:01 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$154,904,0002025-12-3110-K, XBRL RevenueFromContractWithCustomerIncludingAssessedTax2026-11-22 01:01 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-20,195,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-22 01:01 UTCReport an error
Total assets (at 2025-12-31)$255,877,0002025-12-3110-K, XBRL Assets2026-11-22 01:01 UTCReport an error
Stockholders' equity (at 2025-12-31)$14,333,0002025-12-3110-K, XBRL StockholdersEquity2026-11-22 01:01 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$28,647,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 01:01 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-27,591,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 01:01 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$317,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-22 01:01 UTCReport an error
Operating lease liabilities (at 2024-12-31)$3,037,0002024-12-3110-K, XBRL OperatingLeaseLiability2026-11-22 01:01 UTCReport an error
Form D total offering amount (D filed 2023-08-01)$30,000,0002023-08-01D2026-11-22 01:01 UTCReport an error
Form D total amount sold (D filed 2023-08-01)$30,000,0002023-08-01D2026-11-22 01:01 UTCReport an error
Form D industry groupBiotechnology2023-08-01D2026-11-22 01:01 UTCReport an error
Form D revenue rangeDecline to Disclose2023-08-01D2026-11-22 01:01 UTCReport an error
Form D date of first sale2023-07-252023-08-01D2026-11-22 01:01 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-09)On November 9, 2026, Heron Therapeutics, Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2026 (“Earnings Press Release”). A copy of the Earnings Press Release is furnished as Exhibit 99.1. The information in this Item 2.02 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by…2026-11-09SEC EDGAR 8-K 0001193125-26-452721 (text as filed, excerpt)2026-11-22 01:01 UTCReport an error
8-K Item 1.01, Entry into a Material Definitive Agreement (filed 2026-11-09)Asset Purchase Agreement On November 8, 2026, Heron Therapeutics, Inc., a Delaware corporation (the “Company”), and CorMedix Inc., a Delaware corporation (the “Buyer”), entered into an Asset Purchase Agreement (the “Purchase Agreement”), pursuant to which the Company has agreed to sell substantially all of its assets to the Buyer, other than certain excluded assets, including the Company’s federal income tax net operating loss carryforwards (the “NOLs”) and certain other tax attributes, and the Buyer has agreed to acquire those assets and assume certain liabilities of the Company as set forth in the Purchase Agreement (the “Asset Sale” or the “Proposed Transaction”). As consideration for…2026-11-09SEC EDGAR 8-K 0001193125-26-452672 (text as filed, excerpt)2026-11-22 01:01 UTCReport an error
8-K Item 3.03, Material Modification to Rights of Security Holders (filed 2026-11-09)The information included under the heading “Amendment No. 2 to Tax Benefit Preservation Plan” in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.03.2026-11-09SEC EDGAR 8-K 0001193125-26-452672 (text as filed, excerpt)2026-11-22 01:01 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-11-09)On November 9, 2026, the Company and the Buyer issued a joint press release announcing the execution of the Purchase Agreement. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference into this Item 7.01. The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as…2026-11-09SEC EDGAR 8-K 0001193125-26-452672 (text as filed, excerpt)2026-11-22 01:01 UTCReport an error
8-K Item 1.01, Entry into a Material Definitive Agreement (filed 2026-09-29)On September 23, 2026 (the “Effective Date”), Heron Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a multi-product Development and License Agreement (the “License Agreement”) with Long Grove Pharmaceuticals, LLC, a Delaware limited liability company (“Long Grove”), and Capstone Development Services Company, LLC, a Delaware limited liability company (“Capstone”), which provided for, among other things, the grant by Long Grove to the Company of an exclusive (as to the licensed patents), sublicensable license to import, distribute, sell and market certain products in the United States, including its territories, commonwealths and possessions (the “Territory”), and a…2026-09-29SEC EDGAR 8-K 0001193125-26-407728 (text as filed, excerpt)2026-11-22 01:01 UTCReport an error
8-K Item 1.01, Entry into a Material Definitive Agreement (filed 2026-08-14)On August 13, 2026, Heron Therapeutics, Inc. (the “Company”) entered into Amendment No. 1 to Tax Benefit Preservation Plan (the “Amendment”), which amends the Tax Benefit Preservation Plan, dated as of August 14, 2025 (the “Plan”), by and between the Company and Computershare Trust Company, N.A., as rights agent. The Amendment amends the definition of “Final Expiration Date” and all references to August 14, 2026 in the Plan to mean August 14, 2029. The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the Amendment, a copy of which is attached as Exhibit 4.1 and is incorporated herein by reference.2026-08-14SEC EDGAR 8-K 0001193125-26-352403 (text as filed, excerpt)2026-11-22 01:01 UTCReport an error
8-K Item 3.03, Material Modification to Rights of Security Holders (filed 2026-08-14)The information included in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.03.2026-08-14SEC EDGAR 8-K 0001193125-26-352403 (text as filed, excerpt)2026-11-22 01:01 UTCReport an error
Plan (pension, plan no. 001)HERON THERAPEUTICS, INC. 401(K) PLAN: 266 participants, assets $34,514,0212025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-22 01:01 UTCReport an error
Plan (welfare, plan no. 501)HERON THERAPEUTICS, INC. HEALTH AND WELFARE PLAN: 110 participants2025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-22 01:01 UTCReport an error
Largest institutional holder #1 (13F as filed): Rubric Capital Management LP$12,823,9862026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 01:01 UTCReport an error
Largest institutional holder #2 (13F as filed): Clearline Capital LP$4,858,6752026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 01:01 UTCReport an error
Largest institutional holder #3 (13F as filed): BlackRock, Inc.$4,503,0602026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 01:01 UTCReport an error
Largest institutional holder #4 (13F as filed): Velan Capital Investment Management LP$3,735,9042026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 01:01 UTCReport an error
Largest institutional holder #5 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$3,323,2302026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 01:01 UTCReport an error
Largest institutional holder #6 (13F as filed): Tejara Capital Ltd$2,778,8072026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 01:01 UTCReport an error
Largest institutional holder #7 (13F as filed): TANG CAPITAL MANAGEMENT LLC$2,667,5002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 01:01 UTCReport an error
Largest institutional holder #8 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$1,823,4052026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 01:01 UTCReport an error
Largest institutional holder #9 (13F as filed): MILLENNIUM MANAGEMENT LLC$1,737,1192026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 01:01 UTCReport an error
Largest institutional holder #10 (13F as filed): JW Asset Management, LLC$1,600,9582026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 01:01 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.